Switch theme
Sign up to access all valuation multiples
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
2005
514
LTM Revenue $140M
LTM EBITDA $26.6M
$153M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InfuSystem has a last 12-month revenue (LTM) of $140M and a last 12-month EBITDA of $26.6M.
In the most recent fiscal year, InfuSystem achieved revenue of $135M and an EBITDA of $19.3M.
InfuSystem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InfuSystem valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $140M | XXX | $135M | XXX | XXX | XXX |
| Gross Profit | $74.1M | XXX | $70.4M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $26.6M | XXX | $19.3M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $6.9M | XXX | $6.9M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $2.6M | XXX | $2.3M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $23.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, InfuSystem's stock price is $6.
InfuSystem has current market cap of $121M, and EV of $153M.
See InfuSystem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $121M | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, InfuSystem has market cap of $121M and EV of $153M.
InfuSystem's trades at 1.1x EV/Revenue multiple, and 7.9x EV/EBITDA.
Equity research analysts estimate InfuSystem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InfuSystem has a P/E ratio of 46.2x.
See valuation multiples for InfuSystem and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 5.7x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBIT | 22.2x | XXX | 22.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 46.2x | XXX | 51.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 58.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInfuSystem's last 12 month revenue growth is 8%
InfuSystem's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
InfuSystem's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InfuSystem's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for InfuSystem and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 31% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| Senseonics Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InfuSystem acquired XXX companies to date.
Last acquisition by InfuSystem was XXXXXXXX, XXXXX XXXXX XXXXXX . InfuSystem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was InfuSystem founded? | InfuSystem was founded in 2005. |
| Where is InfuSystem headquartered? | InfuSystem is headquartered in United States of America. |
| How many employees does InfuSystem have? | As of today, InfuSystem has 514 employees. |
| Who is the CEO of InfuSystem? | InfuSystem's CEO is Ms. Carrie A. Lachance. |
| Is InfuSystem publicy listed? | Yes, InfuSystem is a public company listed on ASE. |
| What is the stock symbol of InfuSystem? | InfuSystem trades under INFU ticker. |
| When did InfuSystem go public? | InfuSystem went public in 1992. |
| Who are competitors of InfuSystem? | Similar companies to InfuSystem include e.g. Philips, Perspective Therapeutics, SmartVest, Myomo. |
| What is the current market cap of InfuSystem? | InfuSystem's current market cap is $121M |
| What is the current revenue of InfuSystem? | InfuSystem's last 12 months revenue is $140M. |
| What is the current revenue growth of InfuSystem? | InfuSystem revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of InfuSystem? | Current revenue multiple of InfuSystem is 1.1x. |
| Is InfuSystem profitable? | Yes, InfuSystem is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InfuSystem? | InfuSystem's last 12 months EBITDA is $26.6M. |
| What is InfuSystem's EBITDA margin? | InfuSystem's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of InfuSystem? | Current EBITDA multiple of InfuSystem is 5.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
